300194 福安药业
已收盘 07-30 15:00:00
资讯
新帖
简况
福安药业：长效生长激素属于创新药但非公司主导研发
证券之星 · 07-29 07:45
福安药业：长效生长激素属于创新药但非公司主导研发
福安药业(300194.SZ)：注射用丁二磺酸腺苷蛋氨酸完成药品注册
智通财经 · 07-28 08:05
福安药业(300194.SZ)：注射用丁二磺酸腺苷蛋氨酸完成药品注册
福安药业：子公司烟台只楚药业主要产品为庆大霉素原料及制剂
证券之星 · 07-23
福安药业：子公司烟台只楚药业主要产品为庆大霉素原料及制剂
福安药业：公司目前没有被收购合并事项
证券之星 · 07-23
福安药业：公司目前没有被收购合并事项
福安药业：截止7月18日股东户数为41599户
证券之星 · 07-21
福安药业：截止7月18日股东户数为41599户
福安药业(300194.SZ)发预减，预计上半年归母净利润1亿元至1.3亿元，同比下降39.95%至53.81%
智通财经 · 07-18
福安药业(300194.SZ)发预减，预计上半年归母净利润1亿元至1.3亿元，同比下降39.95%至53.81%
福安药业：截止7月10日股东户数为40615户
证券之星 · 07-14
福安药业：截止7月10日股东户数为40615户
福安药业：截止6月30日股东户数为39974户
证券之星 · 07-01
福安药业：截止6月30日股东户数为39974户
福安药业：公司目前的主要业务是化学仿制药的研发、生产、销售
证券之星 · 06-17
福安药业：公司目前的主要业务是化学仿制药的研发、生产、销售
每周股票复盘：福安药业（300194）股东户数增加230户，户均持股减少
证券之星 · 06-07
每周股票复盘：福安药业（300194）股东户数增加230户，户均持股减少
福安药业：截止5月30日，公司股东户数为40760户
证券之星 · 06-05
福安药业：截止5月30日，公司股东户数为40760户
每周股票复盘：福安药业（300194）股东户数减少，每股派发现金股利0.50元
证券之星 · 05-24
每周股票复盘：福安药业（300194）股东户数减少，每股派发现金股利0.50元
福安药业(300194)5月20日股东户数4.05万户，较上期减少4.28%
证券之星 · 05-22
福安药业(300194)5月20日股东户数4.05万户，较上期减少4.28%
福安药业：公司目前账面商誉资产主要是2015年收购宁波天衡形成
证券之星 · 05-22
福安药业：公司目前账面商誉资产主要是2015年收购宁波天衡形成
福安药业：公司有自己的研发管理体系和平台配备有专业研发人员和专业设备
证券之星 · 05-22
福安药业：公司有自己的研发管理体系和平台配备有专业研发人员和专业设备
福安药业：实际控制人主要从以下方面提供持续支持
证券之星 · 05-22
福安药业：实际控制人主要从以下方面提供持续支持
福安药业：公司目前没有实控人是否转让控制权的相关信息
证券之星 · 05-22
福安药业：公司目前没有实控人是否转让控制权的相关信息
福安药业：公司已进入注册程序的研发项目都按规定在定期报告中进行汇总披露
证券之星 · 05-22
福安药业：公司已进入注册程序的研发项目都按规定在定期报告中进行汇总披露
福安药业：公司货币资金真实存在，同时公司子公司也有银行借款
证券之星 · 05-22
福安药业：公司货币资金真实存在，同时公司子公司也有银行借款
福安药业：福安药业集团庆余堂制药有限公司系公司全资子公司
证券之星 · 05-22
福安药业：福安药业集团庆余堂制药有限公司系公司全资子公司
加载更多
公司概况
公司名称：
福安药业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
2011-03-22
主营业务：
福安药业(集团)股份有限公司的主营业务是化学药品的研发、生产、销售。公司的主要产品是庆大霉素、头孢唑肟钠、头孢美唑钠、拉氧头孢钠、头孢他啶、枸橼酸托瑞米芬片（制剂）、盐酸昂丹司琼（原料药、制剂）、盐酸格拉司琼（原料药、制剂）、多索茶碱（原料药、制剂）、尼麦角林胶囊、舒林酸片、谷胱甘肽。
发行价格：
41.88
{"stockData":{"symbol":"300194","market":"SZ","secType":"STK","nameCN":"福安药业","latestPrice":4.74,"timestamp":1753858989000,"preClose":4.69,"halted":0,"volume":62509846,"delay":0,"changeRate":0.0107,"floatShares":968000000,"shares":1190000000,"eps":0.1903,"marketStatus":"已收盘","change":0.05,"latestTime":"07-30 15:00:00","open":4.67,"high":4.79,"low":4.66,"amount":296000000,"amplitude":0.0277,"askPrice":4.74,"askSize":4386,"bidPrice":4.73,"bidSize":2153,"shortable":0,"etf":0,"ttmEps":0.1903,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":4.69,"symbolType":"stock","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":5.16,"lowLimit":4.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1189712382,"isCdr":false,"pbRate":1.26,"roa":"--","peRate":24.90804,"roe":"1.56%","epsLYR":0.24,"committee":-0.368988,"marketValue":5639000000,"turnoverRate":0.0646,"status":0,"floatMarketCap":4588000000},"requestUrl":"/m/hq/s/300194","defaultTab":"news","newsList":[{"id":"2555403380","title":"福安药业：长效生长激素属于创新药但非公司主导研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2555403380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555403380?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:45","pubTimestamp":1753775112,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的长效生长激素不属于一类化药吗？？一类化药不就是创新药？？福安药业回复：长效生长激素研发项目系公司子公司重庆庆余堂参股公司苏州优诺金公司的在研生物制品项目，该药品属于创新药，但其并非由公司主导进行研发的项目，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900022054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","300194","BK0028","BK0132","BK1161","06978","BK0060","BK0239"],"gpt_icon":0},{"id":"2554472915","title":"福安药业(300194.SZ)：注射用丁二磺酸腺苷蛋氨酸完成药品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2554472915","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554472915?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:05","pubTimestamp":1753689916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团烟台只楚药业有限公司(简称“只楚药业”)于近日收到国家药品监督管理局签发的药品注册证书，药品名称为注射用丁二磺酸腺苷蛋氨酸。注射用丁二磺酸腺苷蛋氨酸适用于肝硬化前和肝硬化所致肝内胆汁淤积;适用于妊娠期肝内胆汁淤积。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福安药业(300194.SZ)：注射用丁二磺酸腺苷蛋氨酸完成药品注册","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194","BK0028","BK0239","BK0060","BK0132"],"gpt_icon":0},{"id":"2553029265","title":"福安药业：子公司烟台只楚药业主要产品为庆大霉素原料及制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2553029265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553029265?lang=zh_cn&edition=full","pubTime":"2025-07-23 15:24","pubTimestamp":1753255448,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司山东子公司主要集中在哪里，产品分布是哪些，谢谢福安药业回复：公司子公司烟台只楚药业主要产品为庆大霉素原料及制剂，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300020670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0132","300194","BK0060","BK0239"],"gpt_icon":0},{"id":"2553293258","title":"福安药业：公司目前没有被收购合并事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2553293258","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553293258?lang=zh_cn&edition=full","pubTime":"2025-07-23 11:36","pubTimestamp":1753241788,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司将被金石亚药收购合并？福安药业回复：公司目前没有被收购合并事项，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300016234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0028","BK0239","BK0132"],"gpt_icon":0},{"id":"2553424807","title":"福安药业：截止7月18日股东户数为41599户","url":"https://stock-news.laohu8.com/highlight/detail?id=2553424807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553424807?lang=zh_cn&edition=full","pubTime":"2025-07-21 15:54","pubTimestamp":1753084462,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止7月20日收盘公司的股东人数是多少？谢谢福安药业回复：截止7月18日，公司股东户数为41599户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100017693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300194","BK0132","BK0060"],"gpt_icon":0},{"id":"2552724463","title":"福安药业(300194.SZ)发预减，预计上半年归母净利润1亿元至1.3亿元，同比下降39.95%至53.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552724463","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552724463?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:51","pubTimestamp":1752828672,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)披露2025年半年度业绩预告，公司预计归属于上市公司股东的净利润1亿元至1.3亿元，同比下降39.95%至53.81%;扣除非经常性损益后的净利润9100万元–1.21亿元，同比下降40.50%至55.25%。公告称，随着集采在全国推行，公司主要产品销售价格大幅度下降，营业收入降低，利润空间承压。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"福安药业(300194.SZ)发预减，预计上半年归母净利润1亿元至1.3亿元，同比下降39.95%至53.81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194"],"gpt_icon":0},{"id":"2551997732","title":"福安药业：截止7月10日股东户数为40615户","url":"https://stock-news.laohu8.com/highlight/detail?id=2551997732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551997732?lang=zh_cn&edition=full","pubTime":"2025-07-14 15:12","pubTimestamp":1752477127,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请7月10日公司的股东人数是多少？谢谢福安药业回复：截止7月10日，公司股东户数为40615户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400014489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300194","BK0060","BK0028","BK0239"],"gpt_icon":0},{"id":"2548730540","title":"福安药业：截止6月30日股东户数为39974户","url":"https://stock-news.laohu8.com/highlight/detail?id=2548730540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548730540?lang=zh_cn&edition=full","pubTime":"2025-07-01 15:54","pubTimestamp":1751356458,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问截止今日的股东人数？福安药业回复：截止6月30日，公司股东户数为39974户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100023459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0028","300194","BK0239","BK0132"],"gpt_icon":0},{"id":"2544531149","title":"福安药业：公司目前的主要业务是化学仿制药的研发、生产、销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2544531149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544531149?lang=zh_cn&edition=full","pubTime":"2025-06-17 15:18","pubTimestamp":1750144697,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好福安药业作为一家成立20多年的药企，有没有考虑往生物制药以及创新药方向发展？纵观国内外大药企的发展历程无不是通过创新药发展壮大起来的，汪老作为一名有理想的企业家不可能只着眼于仿制药的研制吧。公司目前的主要业务是化学仿制药的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700017766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2541289245","title":"每周股票复盘：福安药业（300194）股东户数增加230户，户均持股减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2541289245","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541289245?lang=zh_cn&edition=full","pubTime":"2025-06-07 10:00","pubTimestamp":1749261634,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，福安药业报收于4.21元，较上周的4.16元上涨1.2%。本周，福安药业6月4日盘中最高价报4.35元。福安药业当前最新总市值50.09亿元，在化学制药板块市值排名90/150，在两市A股市值排名2940/5148。本周关注点股本股东变化：截至2025年5月30日公司股东户数为4.08万户，较5月20日增加230户股本股东变化近日福安药业披露，截至2025年5月30日公司股东户数为4.08万户，较5月20日增加230.0户，增幅为0.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700009841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300194","BK0028","BK0060","BK0132"],"gpt_icon":0},{"id":"2541012644","title":"福安药业：截止5月30日，公司股东户数为40760户","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012644","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541012644?lang=zh_cn&edition=full","pubTime":"2025-06-05 11:33","pubTimestamp":1749094405,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问截止到2025年5月31日公司股东户数是多少？谢谢福安药业回复：截止5月30日，公司股东户数为40760户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500011497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0239","BK0132","300194"],"gpt_icon":0},{"id":"2537161422","title":"每周股票复盘：福安药业（300194）股东户数减少，每股派发现金股利0.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537161422","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537161422?lang=zh_cn&edition=full","pubTime":"2025-05-24 11:51","pubTimestamp":1748058670,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，福安药业报收于4.14元，较上周的4.18元下跌0.96%。本周，福安药业5月20日盘中最高价报4.28元。公司公告汇总福安药业（集团）股份有限公司2024年度权益分派方案已获2025年5月15日召开的2024年年度股东大会审议通过。公司以现有总股本1189712382股为基数，向全体股东每10股派发现金股利0.50元人民币（含税），共计派发现金股利59485619.10元（含税）。A股股东现金红利将于2025年5月28日通过股东托管证券公司直接划入其资金账户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400011352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300194","BK0028","BK0132"],"gpt_icon":0},{"id":"2537691614","title":"福安药业(300194)5月20日股东户数4.05万户，较上期减少4.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537691614","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537691614?lang=zh_cn&edition=full","pubTime":"2025-05-22 17:17","pubTimestamp":1747905450,"startTime":"0","endTime":"0","summary":"证券之星消息，近日福安药业披露，截至2025年5月20日公司股东户数为4.05万户，较4月20日减少1811.0户，减幅为4.28%。在化学制药行业个股中，福安药业股东户数高于行业平均水平，截至5月20日，化学制药行业平均股东户数为3.22万户。从股价来看，2025年4月20日至2025年5月20日，福安药业区间跌幅为0.0%，在此期间股东户数减少1811.0户，减幅为4.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200026367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0132","BK0028","BK0239"],"gpt_icon":0},{"id":"2537274997","title":"福安药业：公司目前账面商誉资产主要是2015年收购宁波天衡形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2537274997","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537274997?lang=zh_cn&edition=full","pubTime":"2025-05-22 16:03","pubTimestamp":1747900989,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司当前仍然具有高额的商誉存在，高达2.61亿元，请问是否将对公司的正常业绩造成重大不利影响？该项商誉主要是什么时候形成的？以及当前的经营情况如何？谢谢介绍福安药业回复：公司目前账面商誉资产主要是2015年收购宁波天衡形成，目前该子公司经营情况正常，公司每年都会对商誉减值进行测试，按照规定进行处理，目前不会对公司业绩造成重大不利影响，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200021927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0239","BK0132","300194"],"gpt_icon":0},{"id":"2537974519","title":"福安药业：公司有自己的研发管理体系和平台配备有专业研发人员和专业设备","url":"https://stock-news.laohu8.com/highlight/detail?id=2537974519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537974519?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:54","pubTimestamp":1747900467,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司实控人在公司主要负责药品研发吗？福安药业回复：公司有自己的研发管理体系和平台，配备有专业研发人员和专业设备，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200020790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","BK0060","BK0028","300194"],"gpt_icon":0},{"id":"2537974439","title":"福安药业：实际控制人主要从以下方面提供持续支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2537974439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537974439?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:54","pubTimestamp":1747900452,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业05月22日在投资者关系平台上答复投资者关心的问题。实际控制人主要从以下方面提供持续支持：在治理结构方面，确保公司在人员、财务、业务等方面保持独立性，并通过参与董事会决策为公司把握战略方向。作为大股东，始终着眼于公司的长期价值创造，在重大决策上，坚定支持公司发展，积极履行规范运作监督者的职责，旨在为公司营造规范健康的发展环境，最终实现全体股东的长期利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200020750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0132","300194"],"gpt_icon":0},{"id":"2537204992","title":"福安药业：公司目前没有实控人是否转让控制权的相关信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2537204992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537204992?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:42","pubTimestamp":1747899734,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司实控人是否有转让控制权的考虑？福安药业回复：公司目前没有实控人是否转让控制权的相关信息，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200019155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0028","BK0239","BK0060","BK0132"],"gpt_icon":0},{"id":"2537992769","title":"福安药业：公司已进入注册程序的研发项目都按规定在定期报告中进行汇总披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2537992769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537992769?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:39","pubTimestamp":1747899559,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有抗衰老产品？以及公司当前有哪些重磅的在研发的产品？可否向投资者介绍，谢谢。福安药业回复：公司已进入注册程序的研发项目都按规定在定期报告中进行汇总披露，公司目前没有抗衰老产品，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200018860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300194","BK0060","BK0132"],"gpt_icon":0},{"id":"2537927599","title":"福安药业：公司货币资金真实存在，同时公司子公司也有银行借款","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537927599?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:37","pubTimestamp":1747899426,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司财务账上现金丰厚，但是公司的发展战略中却从未提交并购发展，请问主要考虑是什么？公司账上的银行存款是否真实存在？福安药业回复：公司货币资金真实存在，同时公司子公司也有银行借款。公司是否进行并购并不完全取决于资金因素，也要看是否有恰当时机，合适标的，是否有助于公司进一步发展，是否能够提升公司核心竞争能力等方面，因此是一个综合考量的问题，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200018600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0060","BK0132","BK0028","BK0239"],"gpt_icon":0},{"id":"2537992790","title":"福安药业：福安药业集团庆余堂制药有限公司系公司全资子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2537992790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537992790?lang=zh_cn&edition=full","pubTime":"2025-05-22 15:36","pubTimestamp":1747899413,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，庆余堂是公司的注册商标以及下属企业吗？该公司目前具有哪些知名的产品？从名字看，该名字具有一定的文化历史与沉淀，是否有考虑像同仁堂一样发展壮大？请介绍。福安药业回复：您好，福安药业集团庆余堂制药有限公司系公司全资子公司，庆余堂成立于1996年，目前其主要业务为化学制剂的生产，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200018574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0028","BK1574","300194","BK0239","BK1191","01477","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753900322231,"stockEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.1206},{"period":"3month","weight":0.1934},{"period":"6month","weight":0.1054},{"period":"1year","weight":0.2239},{"period":"ytd","weight":0.0758}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0497},{"period":"3month","weight":0.1027},{"period":"6month","weight":0.1123},{"period":"1year","weight":0.2558},{"period":"ytd","weight":0.0788}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"福安药业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41599人(较上一季度增加2.42%)","perCapita":"23267股","listingDate":"2011-03-22","address":"重庆市长寿区化南一路1号","registeredCapital":"118971万元","survey":" 福安药业(集团)股份有限公司的主营业务是化学药品的研发、生产、销售。公司的主要产品是庆大霉素、头孢唑肟钠、头孢美唑钠、拉氧头孢钠、头孢他啶、枸橼酸托瑞米芬片（制剂）、盐酸昂丹司琼（原料药、制剂）、盐酸格拉司琼（原料药、制剂）、多索茶碱（原料药、制剂）、尼麦角林胶囊、舒林酸片、谷胱甘肽。","listedPrice":41.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福安药业,300194,福安药业股票,福安药业股票老虎,福安药业股票老虎国际,福安药业行情,福安药业股票行情,福安药业股价,福安药业股市,福安药业股票价格,福安药业股票交易,福安药业股票购买,福安药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}